LIPO RSI Chart
Last 7 days
4.1%
Last 30 days
1.3%
Last 90 days
-24%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 477.4K | 0 | 0 | 0 |
2023 | 269.1K | 375.7K | 479.8K | 449.6K |
2022 | 240.5K | 221.8K | 203.0K | 184.2K |
2021 | 0 | 0 | 0 | 259.3K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 19, 2024 | kaufman jonathan h | bought | 21,802 | 0.8721 | 25,000 | see remarks below. |
Mar 18, 2024 | kaufman jonathan h | bought | 23,649 | 0.7883 | 30,000 | see remarks below. |
Mar 13, 2024 | kaufman jonathan h | acquired | 99,999 | 0.6901 | 144,906 | see remarks below. |
Mar 13, 2024 | chancellor michael b | acquired | 99,999 | 0.6901 | 144,906 | chief medical officer |
Dec 22, 2022 | chancellor michael b | acquired | 131,962 | 5.75 | 22,950 | chief medical officer |
Which funds bought or sold LIPO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 15,120 | 15,120 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -17.57 | -7,224 | 8,958 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 11.4 | -1,777 | 5,280 | -% |
May 15, 2024 | SABBY MANAGEMENT, LLC | reduced | -7.39 | -104,045,000 | 171,181,000 | 0.10% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -14,100 | 28,831 | -% |
May 13, 2024 | HRT FINANCIAL LP | new | - | 7,000 | 7,000 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -776 | - | -% |
May 13, 2024 | FMR LLC | new | - | 45.00 | 45.00 | -% |
May 10, 2024 | VANGUARD GROUP INC | unchanged | - | -11,564 | 23,646 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 3.45 | -9.00 | 21.00 | -% |
Unveiling Lipella Pharmaceuticals Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Lipella Pharmaceuticals Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Lipella Pharmaceuticals Inc. News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 20.7% | 145,880 | 120,842 | 104,051 | 106,676 | 118,048 | 151,007 | - | - | 33,149 | - |
Operating Expenses | 60.3% | 1,363,526 | 850,436 | 1,460,778 | 1,681,876 | 1,202,480 | 510,269 | 712,642 | 781,147 | 769,812 | - |
S&GA Expenses | -100.0% | - | 396,236 | 627,518 | 624,231 | 508,750 | 32,167 | 61,688 | 38,487 | 93,850 | - |
R&D Expenses | 85.5% | 842,600 | 454,201 | 833,260 | 1,057,645 | 693,730 | 478,102 | 650,954 | 742,660 | 675,962 | - |
EBITDA Margin | 3.2% | -9.92 | -10.25 | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | 5,454 | 5,394 | 4,705 | 1,653 | 1,636 | 1,618 | - |
Earnings Before Taxes | -73.0% | -1,191,809 | -688,884 | -1,323,570 | -1,538,686 | -1,067,825 | -363,924 | -713,794 | -782,024 | -737,950 | - |
EBT Margin | 3.3% | -9.93 | -10.27 | -8.95 | -9.81 | -10.88 | -14.11 | -9.19 | -8.41 | -7.76 | -7.19 |
Net Income | -73.0% | -1,191,809 | -688,884 | -1,323,570 | -1,538,686 | -1,067,825 | -363,924 | -713,794 | -782,024 | -737,950 | - |
Net Income Margin | 3.3% | -9.93 | -10.27 | -8.95 | -9.81 | -10.88 | -14.11 | -9.19 | -8.41 | -7.76 | -7.19 |
Free Cashflow | 100.0% | - | -727,710 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2021Q4 |
Assets | -12.3% | 3,137 | 3,577 | 2,841 | 3,490 | 4,615 | 5,950 | 2,013 |
Current Assets | -12.2% | 3,011 | 3,429 | 2,671 | 3,367 | 4,478 | 5,799 | 1,808 |
Cash Equivalents | -36.1% | 2,105 | 3,294 | 2,410 | 3,114 | 4,019 | 5,122 | 1,414 |
Net PPE | -5.7% | 12.00 | 13.00 | 13.00 | - | - | - | - |
Liabilities | 33.1% | 576 | 433 | 619 | 364 | 798 | 1,275 | 589 |
Current Liabilities | 43.2% | 552 | 385 | 549 | 299 | 717 | 1,178 | 341 |
Shareholder's Equity | -18.5% | 2,561 | 3,144 | 2,222 | 3,125 | 3,816 | 4,676 | 1,424 |
Retained Earnings | -11.5% | -11,515 | -10,323 | -9,634 | -8,311 | -6,772 | -5,704 | -3,107 |
Additional Paid-In Capital | 4.5% | 14,076 | 13,468 | 11,856 | 11,436 | 10,589 | 10,380 | 4,530 |
Accumulated Depreciation | 0.6% | 128 | 128 | 127 | - | - | 126 | - |
Shares Outstanding | 16.3% | 7,040 | 6,054 | 5,804 | 5,744 | 5,744 | 5,744 | 3,867 |
Float | - | - | - | - | 9,608 | - | - | - |
Cashflow (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -90.8% | -1,388 | -727 | -689 | -655 | -1,077 | -231 | -320 | -579 | -699 | - |
Cashflow From Investing | - | - | - | - | - | - | - | - | 601 | -300 | - |
Cashflow From Financing | -87.6% | 200 | 1,612 | - | -250 | -25.00 | - | - | - | - | - |
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenues | $ 145,880 | $ 118,048 |
Cost and expenses | ||
Research and development | 842,600 | 693,730 |
General and administrative | 520,926 | 508,750 |
Total costs and expenses | 1,363,526 | 1,202,480 |
Loss from operations | (1,217,646) | (1,084,432) |
Other income (expense) | ||
Interest income, net | 25,837 | 22,001 |
Interest expense related party | (5,394) | |
Total other income (expense) | 25,837 | 16,607 |
Loss before income taxes | (1,191,809) | (1,067,825) |
Provision for income taxes | ||
Net Loss | $ (1,191,809) | $ (1,067,825) |
Loss per common share | ||
Basic | $ (0.16) | $ (0.19) |
Dilutive | $ (0.16) | $ (0.19) |
Weighted-average of common shares outstanding: | ||
Basic | 7,292,396 | 5,743,945 |
Dilutive | 7,292,396 | 5,743,945 |
Grantrevenues [Member] | ||
Total revenues | $ 145,880 | $ 118,048 |
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 2,105,299 | $ 3,293,738 |
Grants receivable | 68,934 | 32,286 |
Prepaid expenses | 836,857 | 103,256 |
Total Current Assets | 3,011,090 | 3,429,280 |
Property and Equipment | ||
Furniture, fixtures and equipment | 140,294 | 140,294 |
Furniture, fixtures and equipment (Accumulated Depreciation) | (128,265) | (127,544) |
Furniture and fixtures, net | 12,029 | 12,750 |
Other Assets | ||
Operating lease right of use asset | 114,038 | 135,144 |
Total Assets | 3,137,157 | 3,577,174 |
Current liabilities | ||
Accounts payable | 293,835 | 138,016 |
Accrued expenses | 84,929 | 77,280 |
Operating lease liability | 91,705 | 89,223 |
Payroll liability | 81,412 | 80,836 |
Total Current Liabilities | 551,881 | 385,355 |
Operating lease liability, net of current portion | 23,997 | 47,371 |
Total Liabilities | 575,878 | 432,726 |
Stockholders’ equity: | ||
Convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized; -0- shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized, 7,039,846 and 6,053,956 shares issued and outstanding at March 31, 2024 and at December 31, 2023, respectively | 704 | 605 |
Additional paid-in capital | 14,076,227 | 13,467,686 |
Accumulated deficit | (11,515,652) | (10,323,843) |
Total stockholders’ equity | 2,561,279 | 3,144,448 |
Total liabilities and stockholders’ equity | $ 3,137,157 | $ 3,577,174 |